Angiotensin II Type I Receptor -168A/G Polymorphism is Associated withIncreased the Risk of Glioma

Abstract

Gliomas are the most common primary tumors of CNS. Despite advance in elucidation of molecular pathogenesis, gliomas still remains incurable. In the study, it was aimed to investigate possible connection between ACE, AGTR1 polymorphism with glioma pathogenesis and also relationship between some angiogenic markers and gliomagenesis. 96 patients and 104 controls were included. ACE I/D, AGTR1 -168A/G, AGTR1 -535C/T, AGTR1 -825T/A, VEGF +936C/T and VEGF -2578C/A polymorphisms were investigated by PCR-RFLP. Allele/genotype frequencies between patients and controls were determined. Relative gene expressions of ACE, AGTR1 and VEGF were detected by Real Time-PCR while, ACE, VEGF, ET-1, eNOS and NO levels were measured in both serum and tissue by ELISA. In AGTR1 -168A/G polymorphism, the risk of glioma in AA genotype decreased, while increased by 2.27 times in G allele. Allele frequency and genotype distributions of other polymorphisms were found similar between two groups. Serum ACE, VEGF, eNOS, NO and tissue ACE, ET-1, eNOS, NO were also different between patients and controls. ACE, AGTR1 and VEGF expressions of patients were found significantly higher than controls. This results provide the first evidence linking polymorphism in AGTR1 -168A/G with glioma risk in Turkish population.